Table 3. Meta-Regression Analysis of the Accuracy of the Viable Category Using LR-TR and mRECIST Criteria.

Criterion	Covariates (Number of Studies)		Sensitivity (95% CI)	Specificity (95% CI)	p-Value
LR-TR viable	Most common etiology of liver disease				0.21
		Hepatitis B (n = 3)	62 (53, 71)	93 (88, 97)
		Hepatitis C (n = 2)	39 (22, 57)	91 (81, 100)
	MRI contrast agent				0.62
		Hepatobiliary agent (n = 2)	58 (39, 76)	94 (90, 98)
		Extracellular agent or both (n = 3)	59 (39, 78)	90 (82, 98)
	Type of LRT				> 0.99
		TARE only (n = 1)	100 (100, 100)	100 (100, 100)
		Others (n = 4)*	57 (57, 57)	92 (92, 92)
	Image analysis				0.46
		Multiple independent reviewers (n = 3)	64 (48, 80)	94 (89, 98)
		Multiple reviewers with consensus (n = 2)	50 (33, 68)	91 (84, 99)
	Percentage of viable HCC				0.50
		≥ 50% (n = 2)	58 (33, 84)	95 (90, 99)
		< 50% (n = 3)	58 (43, 73)	90 (84, 97)
mRECIST viable	Most common etiology of liver disease				0.01
		Hepatitis B (n = 3)	59 (50, 69)	92 (87, 97)
		Hepatitis C (n = 2)	43 (24, 63)	69 (50, 88)
	MRI contrast agent				0.08
		Hepatobiliary agent (n = 2)	54 (39, 69)	94 (90, 98)
		Extracellular agent or both (n = 3)	55 (38, 73)	78 (67, 89)
	Type of LRT				0.01
		TARE only (n = 1)	100 (100, 100)	50 (14, 86)
		Others (n = 4)*	54 (43, 65)	91 (86, 97)
	Image analysis				0.25
		Multiple independent reviewers (n = 3)	68 (47, 89)	85 (72, 99)
		Multiple reviewers with consensus (n = 2)	48 (30, 66)	86 (71, 100)
	Percentage of viable HCC				0.09
		≥ 50% (n = 2)	58 (10, 100)	84 (66, 100)
		< 50% (n = 3)	55 (41, 69)	87 (75, 100)

^*Conventional TACE was used the most commonly in the four studies.

CI = confidence interval, HCC = hepatocellular carcinoma, LRT = locoregional therapy, LR-TR = Liver Imaging Reporting and Data System Treatment Response, mRECIST = modified Response Evaluation Criteria in Solid Tumors, TACE = transarterial chemoembolization, TARE = transarterial radioembolization